First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH

First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at ASH